BioPharmSignal logoBioPharmSignal

Biotech News

Terns Announces Pricing of Upsized $650 Million Public Offering

Terns Pharmaceuticals (TERN)Terns PharmaceuticalsFinancing

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 16,250,000 shares of its common stock at a public offering

Open original release

Related news

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

RLAYRelay Therapeutics2026-05-21 00:21 EST

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RLAYRelay Therapeutics2026-05-19 20:03 EST

Relay Therapeutics Announces Proposed Public Offering of Common Stock

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

INBXInhibrx2026-07-16 13:00 EST

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

REGNRegeneron Pharmaceuticals2026-05-15 18:09 EST

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

View all latest news

Terns Pharmaceuticals

Terns Pharmaceuticals is a small-molecule biotech focused on oncology and metabolic disease opportunities. Its pipeline is built around targeted therapies with room for multiple shots on goal.

Recent company news

TERNTerns Pharmaceuticals2026-04-27 12:05 EST

Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

TERNTerns Pharmaceuticals2026-04-02 20:05 EST

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

TERNTerns Pharmaceuticals2026-03-25 10:48 EST

Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)

TERNTerns Pharmaceuticals2026-02-25 21:05 EST

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

TERNTerns Pharmaceuticals2026-01-07 21:05 EST

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close
52.95 USD
Market cap
6.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States